Skip to main content

Table 1 Characteristics of patients with mucinous carcinoma and infiltrating ductal carcinoma

From: Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women

  

MC (n = 93)

IDC (n = 2,674)

P

Age, years,

   
 

mean (SD)

49.77 (13.76)

50.68 (11.39)

0.529

 

median

45.88

49.22

 
 

range

28, 85

15, 89

 

Tumor size, cm,

  

0.185

 

mean (SD)

3.06 (2.55)

2.69 (1.65)

 
 

median

2.50

2.30

 
 

range

0.20, 17.0

0.10, 15.0

 

Tumor stage, n (%),

  

0.480

 

T1

29 (34.12)

1123 (42.00)

 
 

T2

47 (55.29)

1297 (48.50)

 
 

T3

7 (8.24)

178 (6.66)

 
 

T4

2 (2.35)

76 (2.84)

 
 

unknown or other

8

0

 

Grade, n (%),

  

<0.0001

 

I

22 (66.67)

251 (14.13)

 
 

II

11 (33.33)

994 (55.97)

 
 

III

0 (0)

531 (29.90)

 
 

unknown or other

60

898

 

Lymphovascular invasion, n (%),

  

<0.0001

 

present

10 (15.38)

996 (47.41)

 
 

absent

55 (84.62)

1105 (52.59)

 
 

unknown or other

28

573

 

ER status, n (%),

  

<0.0001

 

positive

84 (90.32)

1715 (65.28)

 
 

negative

9 (9.68)

912 (34.72)

 
 

unknown or other

0

47

 

PR status, n (%),

  

<0.0001

 

positive

74 (79.57)

1555 (59.19)

 
 

negative

19 (20.43)

1072 (40.81)

 
 

unknown or other

0

47

 

HER2/neu gene overexpression status, n (%),

  

0.023

 

positive

8 (9.88)

467 (19.95)

 
 

negative

73 (90.12)

1874 (80.05)

 
 

unknown or other

12

333

 

Lymph node status, n (%),

  

<0.0001

 

positive

17 (19.77)

1144 (43.73)

 
 

negative

69 (80.23)

1472 (56.27)

 
 

not evaluated

7

58

 

Primary treatment, n (%),

  

0.660

 

mastectomy

59 (64.84)

1735 (67.27)

 
 

lumpectomy with RT

30 (32.97)

751 (29.12)

 
 

lumpectomy without RT

2 (2.20)

93 (3.61)

 
 

no surgery

2

95

 

Systemic therapy, n (%),

  

<0.0001

 

endocrine therapy alone

37 (44.05)

523 (21.02)

 
 

chemotherapy alone

6 (7.14)

603 (24.24)

 
 

endocrine therapy with chemotherapy

41 (48.81)

1362 (54.74)

 
 

none

8

186

 
 

unknown

1

0

 

Follow up time, months

   
 

median

56

55

 
 

range

1.97-142

0.30-142

 

10-year overall survival rate

0.9447

0.8611

0.042

  1. MC pure mucinous carcinoma, IDC infiltrating ductal carcinoma, ER estrogen receptor, PR progesterone receptor, RT radiotherapy.